Global Rheumatoid Arthritis Drugs Market 2018-2022

関節リウマチ治療薬の世界市場2018-2022

◆タイトル:Global Rheumatoid Arthritis Drugs Market 2018-2022
◆商品コード:IRTNTR20599
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年11月12日
◆ページ数:111
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥364,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥520,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、関節リウマチ治療薬の世界市場について調査・分析し、市場概要、市場環境、関節リウマチ治療薬市場規模、分子種類別(生物製剤、小分子)分析、種類別(血清陽性、血清陰性)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・関節リウマチ治療薬の世界市場概要
・関節リウマチ治療薬の世界市場環境
・関節リウマチ治療薬の世界市場動向
・関節リウマチ治療薬の世界市場規模
・関節リウマチ治療薬の世界市場:業界構造分析
・関節リウマチ治療薬の世界市場:分子種類別(生物製剤、小分子)
・関節リウマチ治療薬の世界市場:種類別(血清陽性、血清陰性)
・関節リウマチ治療薬の世界市場:地域別市場規模・分析
・関節リウマチ治療薬の北米市場規模・予測
・関節リウマチ治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・関節リウマチ治療薬のアジア太平洋市場規模・予測
・関節リウマチ治療薬の主要国分析
・関節リウマチ治療薬の世界市場:意思決定フレームワーク
・関節リウマチ治療薬の世界市場:成長要因、課題
・関節リウマチ治療薬の世界市場:競争環境
・関節リウマチ治療薬の世界市場:関連企業情報(ベンダー分析)

107 pages, November 2018
About this market
The use of biologics and biosimilars for the treatment of RA is likely to help the market grow. Unlike synthetic DMARDs, biologics have targeted mechanisms of action and serve as promising molecules for the successful treatment of RA. Technavio’s analysts have predicted that the rheumatoid arthritis drugs market will register a CAGR of close to 8% by 2022.
Market Overview
Increasing need for affordable biologics for rheumatoid arthritis
Unlike conventional DMARDs, such as nonsteroidal anti-inflammatory drugs (NSAIDs) that simply provide symptomatic relief, biologics are considered a more effective medication for management of rheumatoid arthritis.
Low access to healthcare due to social stigma
Social stigma associated with RA mainly due to physical deformities and functional limitations in RA patients. Various strategies are being adopted to tackle social stigma at the patient level.
For the detailed list of factors that will drive and challenge the growth of the rheumatoid arthritis drugs market during the 2018-2022, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Amgen and Novartis the competitive environment is quite intense. Factors such as the use of biologics and biosimilars for the treatment of RA and increasing need for affordable biologics for rheumatoid arthritis, will provide considerable growth opportunities to rheumatoid arthritis drugs manufactures. AbbVie, Amgen, Novartis, Pfizer, UCB Pharma, and Johnson & Johnson are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. Many established rheumatoid arthritis drug companies are vying for their share of the global rheumatoid arthritis drugs market, and players must differentiate themselves to gain vital traction over their competitors.’

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: PIPELINE ANALYSIS
• Pipeline analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: MARKET SEGMENTATION BY TYPE OF MOLECULE
• Segmentation by type of molecule
• Comparison by type of molecule
• Biologics – Market size and forecast 2017-2022
• Small molecules – Market size and forecast 2017-2022
• Market opportunity by type of molecule
PART 09: MARKET SEGMENTATION BY TYPE OF RA
• Segmentation by type of RA
• Seropositive RA
• Seronegative RA
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
• High cost of RA drugs
• Use of biologics/biosimilars for treatment of RA
• Use of gene therapy for RA treatment
• Market dominance by TNF-alpha inhibitors
• Need for rheumatologists
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie
• Amgen
• Johnson & Johnson
• Novartis
• Pfizer
• UCB Pharma
PART 17: APPENDIX
List of abbreviations



Exhibit 01: Parent market
Exhibit 02: Global immunology market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for RA
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global – Market size and forecast 2017-2022 ($ bn)
Exhibit 10: Global – Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2017
Exhibit 19: Type of molecule – Market share 2017-2022 (%)
Exhibit 20: Comparison by type of molecule
Exhibit 21: Biologics – Market size and forecast 2017-2022 ($ bn)
Exhibit 22: Biologics – Year-over-year growth 2018-2022 (%)
Exhibit 23: Small molecules – Market size and forecast 2017-2022 ($ bn)
Exhibit 24: Small molecule – Year-over-year growth 2018-2022 (%)
Exhibit 25: Market opportunity by type of molecule
Exhibit 26: Customer landscape
Exhibit 27: Global – Market share by geography 2017-2022 (%)
Exhibit 28: Regional comparison
Exhibit 29: Americas – Market size and forecast 2017-2022 ($ bn)
Exhibit 30: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 31: Top 3 countries in Americas
Exhibit 32: EMEA – Market size and forecast 2017-2022 ($ bn)
Exhibit 33: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 34: Top 3 countries in EMEA
Exhibit 35: APAC – Market size and forecast 2017-2022 ($ bn)
Exhibit 36: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in APAC
Exhibit 38: Market opportunity
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: AbbVie – Overview
Exhibit 45: AbbVie – Business segments
Exhibit 46: AbbVie – Organizational developments
Exhibit 47: AbbVie – Geographic focus
Exhibit 48: AbbVie – Segment focus
Exhibit 49: AbbVie – Key offerings
Exhibit 50: Amgen – Overview
Exhibit 51: Amgen – Business segments
Exhibit 52: Amgen – Organizational developments
Exhibit 53: Amgen – Geographic focus
Exhibit 54: Amgen – Segment focus
Exhibit 55: Amgen – Key offerings
Exhibit 56: Johnson & Johnson – Overview
Exhibit 57: Johnson & Johnson – Business segments
Exhibit 58: Johnson & Johnson – Organizational developments
Exhibit 59: Johnson & Johnson – Geographic focus
Exhibit 60: Johnson & Johnson – Segment focus
Exhibit 61: Johnson & Johnson – Key offerings
Exhibit 62: Novartis – Overview
Exhibit 63: Novartis – Business segments
Exhibit 64: Novartis – Organizational developments
Exhibit 65: Novartis – Geographic focus
Exhibit 66: Novartis – Segment focus
Exhibit 67: Novartis – Key offerings
Exhibit 68: Pfizer – Overview
Exhibit 69: Pfizer – Business segments
Exhibit 70: Pfizer – Organizational developments
Exhibit 71: Pfizer – Geographic focus
Exhibit 72: Pfizer – Segment focus
Exhibit 73: Pfizer – Key offerings
Exhibit 74: UCB Pharma – Overview
Exhibit 75: UCB Pharma – Business segments
Exhibit 76: UCB Pharma – Organizational developments
Exhibit 77: UCB Pharma – Geographic focus
Exhibit 78: UCB Pharma – Segment focus
Exhibit 79: UCB Pharma – Key offerings



【掲載企業】

AbbVie、Amgen、Johnson & Johnson、Novartis、Pfizer、UCB Pharma

★調査レポート[関節リウマチ治療薬の世界市場2018-2022] (Global Rheumatoid Arthritis Drugs Market 2018-2022 / IRTNTR20599)販売に関する免責事項
[関節リウマチ治療薬の世界市場2018-2022] (Global Rheumatoid Arthritis Drugs Market 2018-2022 / IRTNTR20599)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆